Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Welcome and Introduction to Vi3C

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Amit Sanyal, MD: A Clinician’s Perspective

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement

Sep

16

Today In Oncology

Ivonescimab Significantly Improves Overall Survival vs Pembrolizumab in PD-L1–Positive Advanced NSCLC

Izalontamab Brenitecan Active in Previously Treated EGFR NSCLC

DAROL Examines Darolutamide With Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer

MAVERICK Trial Supports Brain MRI Surveillance Alone as Standard of Care for SCLC

New Executive Director of the Duke Cancer Institute Named

Advertisement

© 2026 HSP News Service, L.L.C.